Australia approval marks a key step in expanding access to the first and only broad coverage vaccine against MenB disease[1],[2];Bexsero was granted European licensure this past January[1]

• MenB disease is a leading cause of meningitis and sepsis globally, and causes approximately 85 percent of all meningococcal disease cases in Australia[3],[4],[5]

• Bexsero safety and efficacy have been shown through clinical trials involving more than 8,000 people including infants, children, adolescents and adults[6]

Basel, August 15, 2013 – Novartis announced today that the Australian Therapeutic Goods Administration (TGA) has added Bexsero®, a multi-component Meningococcal B (MenB) vaccine (recombinant, adsorbed) suspension for injection 0.5 ml pre-filled syringe, to the Australian Register of Therapeutic Goods (ARTG) for use in individuals from two months of age and older[6]. Bexsero is the first and only broad coverage vaccine to help protect all age groups against MenB disease, including infants who are at the greatest risk of infection read all at……………

http://www.pharmalive.com/novartis-bexsero-okd-in-australia